Sort
10,766 grants matching “checkpoint inhibitor”
Patient-Specific Mutation-Derived Tumor Neoantigens as Targets for Cancer Immunotherapy in Smoldering Multiple Myeloma
$221,198Samir Parekh · Icahn School Of Medicine At Mount Sinai · R21 · FY2018 · CA
Bronchoscopic Cryo-Immunotherapy of Lung Cancer
$221,198Daniel Sterman · New York University School Of Medicine · R21 · FY2019 · CA
Evaluation of TERT promoter mutations as melanoma biomarkers in tumors and plasma
$221,198David Polsky · New York University School Of Medicine · R21 · FY2016 · CA
Identification of Novel Regulators of Natural Killer Cell Activity
$221,186Dan S Kaufman · University Of California, San Diego · R21 · FY2021 · CA
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers
$221,186Albert J. Wong · Stanford University · R21 · FY2021 · CA
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin
$220,686Komaraiah Palle · University Of South Alabama · R01 · FY2013 · GM
Targeting Tryptophan Dioxygenase Degradation for Suppression of Tumor Immune Evasion
$220,632Ryan A Altman · Purdue University · R21 · FY2022 · CA
PIK3CA signaling and pancreatic cancer
$220,554Richard Z Lin · State University New York Stony Brook · R21 · FY2023 · CA
Project 3- Integrated Stress and Interferon Responses
$220,450Serge Y Fuchs · University Of Pennsylvania · P01 · FY2022 · CA
Effect of oncolytic herpesvirus on the tumor microenvironment
$220,399Paul Rider · Lsu Health Sciences Center · P20 · FY2021 · GM
Bcl-2 Proteins in Mechanism of Anti-mitotic Drug Action
$220,391Timothy C Chambers · Univ Of Arkansas For Med Scis · R01 · FY2014 · CA
Modulating the immuno-metabolic interplay in liver cancer with cryoablation
$220,198Daniel Coman · Yale University · R21 · FY2024 · CA
Cancer therapy with a combination of oncolytic bacteria and virus to enhance targeted cell killing and anti-tumor immune responses
$220,193Wei Kong · Arizona State University-Tempe Campus · R21 · FY2021 · CA
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members
$220,035Jill E Bargonetti · Hunter College · S06 · FY2007 · GM
Function of TCF-1 in antagonizing malignancy
$220,000Zuoming Sun · Beckman Research Institute/City Of Hope · R21 · FY2021 · AI
Full Project 2: I CARE (Immunotherapy Cutaneous Adverse events REsearch)
$220,000Neil J Shah · Sloan-Kettering Inst Can Research · U54 · FY2024 · CA
Full Project 2: I CARE (Immunotherapy Cutaneous Adverse events Research)
$220,000Neil J Shah · Sloan-Kettering Inst Can Research · U54 · FY2025 · CA
A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy
$219,788Sindy Kam-Yan Tang · Stanford University · R21 · FY2022 · CA
RAPAMYCIN BLOCKADE OF PROTEIN PHOSPHATASE SIGNALING
$219,591David L. Brautigan · University Of Virginia · R01 · FY2006 · CA
Project 2: Chemotherapy-induced Immunomodulation in Colon Cancer
$219,560Temesgen Samuel · Tuskegee University · U54 · FY2021 · CA
ULK1 Inhibitor in Combination with Immune Checkpoint Blockade in PancreaticCancer
$219,491Jeffrey Paul Mackeigan · Michigan State University · R21 · FY2023 · CA
Therapeutic potential of targeting DNA repair deficiency in TSC
$219,491Jeffrey Paul Mackeigan · Michigan State University · R21 · FY2021 · CA
Preoperative immunotherapy in Hepatocellular Carcinoma
$219,491Gregory B. Lesinski · Emory University · R21 · FY2023 · CA
Exploring immune surveillance in isocitrate dehydrogenase mutant cholangiocarcinoma
$218,970Supriya K Saha · Fred Hutchinson Cancer Research Center · R21 · FY2018 · CA
Red-light driven targeted degradation of cancer proteins
$218,886Neel H Shah · Columbia Univ New York Morningside · R61 · FY2025 · CA